InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Arcutis Biotherapeutics, Inc.

ARQT Clue Score48
United States Fiscal year ends December CIK 0001787306 Results filed 4 Nov 2026
Add to watchlist

What the insiders did Net buying

Individual transactions

18
Insider
Date
Role
Action
Shares
Price
Amount
Patrick J Heron
13 Jun 2025
Director
Buy indirect
2,646
$13.08
$34.61K
Patrick J Heron
5 Jun 2025
Director
Buy indirect
378
$13.41
$5.07K
Patrick J Heron
4 Jun 2025
Director
Buy indirect
1,890
$13.32
$25.18K
Patrick J Heron
22 May 2025
Director
Buy indirect
2,520
$13.65
$34.40K
Patrick J Heron
21 May 2025
Director
Buy indirect
2,520
$13.66
$34.42K
Patrick J Heron
15 May 2025
Director
Buy indirect
2,520
$13.62
$34.32K
Patrick J Heron
14 May 2025
Director
Buy indirect
6,300
$13.76
$86.69K
Patrick J Heron
13 May 2025
Director
Buy indirect
2,374
$13.76
$32.66K
Patrick J Heron
9 May 2025
Director
Buy indirect
6,300
$13.60
$85.69K
Todd Watanabe
30 Nov 2024
See Remarks
Buy
2,038
$7.11
$14.48K
Masaru Matsuda
30 Nov 2024
See Remarks
Buy
1,657
$7.11
$11.77K
Larry Todd Edwards
30 Nov 2024
See Remarks
Buy
1,093
$7.11
$7.77K
Todd Watanabe
31 May 2024
See Remarks
Buy
4,000
$1.69
$6.77K
Masaru Matsuda
31 May 2024
See Remarks
Buy
4,000
$1.69
$6.77K
Patrick J Heron
4 Mar 2024
Director
Buy indirect
21,052
$9.50
$199.99K
Frazier Life Sciences VIII, L.P.
24 Oct 2023
10% owner
Buy
80,000
$2.50
$200.00K
Todd Watanabe
31 May 2023
See Remarks
Buy
1,463
$6.38
$9.33K
Frazier Life Sciences VIII, L.P.
5 Aug 2022
10% owner
Buy
250,000
$20.00
$5.00M
Showing 250 of 407 transactions. The figures above use every one of them.

What was left out

Form 4 filings counted 397
Amendments (4/A) skipped 14
Filings about a different issuer 0
Unreadable filings 0
Joint filings 9
Sales on a Rule 10b5-1 plan 126
Sales straight out of an exercise 112
Sales at will 110
Transactions with no price 0
Shares from compensation/vesting 37,290,752
Sales filed before the plan box existed 97
History held since 3 Feb 2020